Abcuro IncProfile last edited on: 1/31/2020
90 Bridge StreetSuite 100Newton, MA 02458
|
Business Identifier: Next generation of T-Cell targeted bio-therapeutics
Public Profile:
A biopharmaceutical company, Acuro Inc.'s promising new target for cancer immunotherapy - KLRG1 - is part of the firm's effort to address developopment of a new generation of immunomodulatory therapeutics for treating both autoimmunity and cancer. The company uses proprietary analysis of transcriptome data from human disease to identify new approaches to target key compartments of the immune system. KLRG1 has recently emerged as an attractive target to restore anti-tumor immune function. An inhibitory receptor of T and NK cells, it functions to reduce the activity of highly differentiated immune cells by interacting with its ligands E/N cadherin. Abcuro has developed a blocking antibody directed toward KLRG1 that restores immune function.
A biopharmaceutical company, Acuro Inc.'s promising new target for cancer immunotherapy - KLRG1 - is part of the firm's effort to address developopment of a new generation of immunomodulatory therapeutics for treating both autoimmunity and cancer. The company uses proprietary analysis of transcriptome data from human disease to identify new approaches to target key compartments of the immune system. KLRG1 has recently emerged as an attractive target to restore anti-tumor immune function. An inhibitory receptor of T and NK cells, it functions to reduce the activity of highly differentiated immune cells by interacting with its ligands E/N cadherin. Abcuro has developed a blocking antibody directed toward KLRG1 that restores immune function.
|
|||||||||||||||||||||||||||||||||||||||
Unlock access
To unlock access to all SBIR-STTR company Profiles, a FREE site registration is required. Click here to register or login if you already have an account
To unlock access to all SBIR-STTR company Profiles, a FREE site registration is required. Click here to register or login if you already have an account Smart Office Options
|
|
SBIR firms in the news
Processing...